Regen BioPharma Inc (RGBP)

[Skiluc]

Read This!! On September 23, 2021 Regen Biopharma, Inc. was granted a Notice of Allowance on the Patent application titled “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” by the United States Patent and Trademark Office.

The invention relates to compounds useful to alteration of NR2F6 activity.

A Notice of Allowance is a document sent to a patent applicant from the United States Patent and Trademark Office (USPTO) after a patent examiner has decided to issue the requested patent.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1589150/000160706221000355/rgbp092721form8k.htm

Regen BioPharma's Medicinal Chemistry Program Has Identified Additional Compounds That Activate NR2F6

The company is rapidly expanding the number of activating compounds in its portfolio

SAN DIEGO, January 17, 2018 /PRNewswire/ --

Regen BioPharma (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization.

"We recently identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. In order to ensure that we capture as much intellectual property as possible, we screened a new 48,000 compound library containing diverse compounds," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "In doing so, we identified 25 new compounds that activate NR2F6. Remarkably, each newly-identified compound contained the key structure that we previously identified. This tells us that it is likely the key structural element we identified is an absolute requirement for activating NR2F6. We anticipate utilizing our three-dimensional x-ray crystallography program to attempt to provide a clear molecular picture of this recently identified element."

"This additional information supports our prior work in this area and gives us confidence we are indeed on the right path," says David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. "I am delighted that the agonist program is moving ahead in such a positive manner."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

https://www.biospace.com/article/releases/regen-biopharma-inc-s-medicinal-chemistry-program-has-identified-additional-compounds-that-activate-nr2f6


Undeniable.